Acrivon Therapeutics (ACRV) vs Clene (CLNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Acrivon Therapeutics (ACRV) has outperformed Clene (CLNN) over the past year, losing 50.0% versus a loss of 62.0%. Clene is the larger company by market cap ($50.7 million vs $49.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | CLNN |
|---|---|---|
| Share price | $1.15 | $3.52 |
| Market cap | $49.35M | $50.69M |
| 1-day change | -17.86% | +0.57% |
| YTD return | -52.28% | -40.03% |
| 1-year return | -50.00% | -62.03% |
| 5-year return | — | -96.28% |
| EPS (TTM) | $-1.82 | $-2.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $200.00K |
| Revenue growth (YoY) | — | -41.52% |
| Net income (latest FY) | $-77.91M | $-26.17M |
| Gross margin | — | 78.50% |
| Operating margin | — | -11541.50% |
| Net margin | — | -13086.50% |
| 52-week high | $3.56 | $10.84 |
| 52-week low | $0.9709 | $3.02 |
| Distance from 52-week high | -67.70% | -67.53% |
| Analyst consensus | none | none |
| Avg. price target upside | +900.00% | +814.77% |
| Average volume | 275.69K | 115.06K |
| Shares outstanding | 42.91M | 14.40M |
| Employees | 74 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRV has outperformed CLNN by 12.0 percentage points over the past year.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
ACRV vs CLNN FAQ
Which is bigger, Acrivon Therapeutics or Clene?
Clene (CLNN) is larger, with a market capitalization of $50.69M compared with $49.35M for Acrivon Therapeutics (ACRV).
Which stock has performed better over the past year, ACRV or CLNN?
ACRV returned -50.00% over the past 12 months, compared with -62.03% for CLNN (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and Clene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.